Scarica l'app Stockscreener
0.76
23.85%
-0.238
Dopo l'orario di chiusura:
.73
-0.03
-3.95%
Precedente Chiudi:
$0.998
Aprire:
$0.87
Volume 24 ore:
14.36M
Relative Volume:
1.18
Capitalizzazione di mercato:
$10.93M
Reddito:
-
Utile/perdita netta:
$-23.36M
Rapporto P/E:
-1.0315
EPS:
-0.7368
Flusso di cassa netto:
-
1 W Prestazione:
+209.19%
1M Prestazione:
+120.99%
6M Prestazione:
-16.94%
1 anno Prestazione:
-49.87%
Intervallo 1D:
$0.70
$0.955
Intervallo di 1 settimana:
$0.2249
$1.60
Portata 52W:
$0.2027
$3.89
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Nome
Calidi Biotherapeutics Inc
Settore
Industria
Telefono
(858) 794-9600
Indirizzo
4475 Executive Drive, Suite 200, San Diego
Confronta CLDI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.76 | 10.93M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-10-09 | Iniziato | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Borsa (CLDI) Ultime notizie
Top Penny Stocks To Add to Your Watchlist – July 9th - Defense World
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Calidi Biotherapeutics: Redefining Cancer Treatment with Breakthrough Virotherapy - AInvest
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment - The Manila Times
Breakthrough Cancer Treatment: Calidi's New Genetic Platform Targets Both Primary and Metastatic Tumors - Stock Titan
Calidi Biotherapeutics Cashes In On Warrant Agreement - Finimize
Calidi Biotherapeutics secures $4.6 million through warrant exercise By Investing.com - Investing.com Nigeria
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds - GlobeNewswire
Clinical-Stage Biotech Calidi Raises $4.6M in Fresh Capital: Accelerates Targeted Therapy Programs - Stock Titan
Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers - FinancialContent
Calidi Biotherapeutics Stock Soars 174.93% on Precision Medicine Hype - AInvest
Calidi Biotherapeutics Soars 119.7% on Cancer Trial News - AInvest
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On - Benzinga
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment - Yahoo Finance
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs – Company AnnouncementFT.com - Financial Times
Calidi Biotherapeutics (CLDI): A Breakthrough in Systemic Virotherapy and the $564B Oncology Opportunity - AInvest
Calidi Biotherapeutics (NYSE:CLDI) Shares Up 5.6% – Still a Buy? - Defense World
CLDI SEC FilingsCalidi Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatment - ACCESS Newswire
Certain Warrants of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Calidi Bio's Revolutionary Cancer Platform RedTail Races to Clinical Trials: CEO Reveals 2026 Timeline - Stock Titan
Millennium Management LLC Increases Stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma, PhD, as CEO to Lead Next Growth Phase - citybuzz -
Jane Street Group LLC Takes Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025 - citybuzz -
Calidi Biotherapeutics Presents systemic oncolytic platform - GlobeNewswire
Calidi Biotherapeutics (CLDI) Showcases Innovative CLD-401 Thera - GuruFocus
Revolutionary Cancer Treatment Breakthrough: Calidi's New Systemic Delivery Platform Wows ASCO Conference - Stock Titan
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting - The Manila Times
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Shares Down 5.3% – Time to Sell? - Defense World
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results And Recent Operational Highlights - marketscreener.com
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Biotherapeutics Secures FDA Green Light for Cancer Trial as New CEO Reveals Q1 Financials - Stock Titan
Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World
Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
CLDICalidi Biotherapeutics Inc Latest Stock News & Market Updates - Stock Titan
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World
Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX
Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus
Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire
Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan
Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan
Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa
Zealand names former Lilly exec Singh as CSO - BioCentury
Calidi Biotherapeutics Inc Azioni (CLDI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.10%
1.57%
Capitalizzazione:
|
Volume (24 ore):